Schwalm Martin P, Menge Amelie, Elson Lewis, Greco Francesco A, Robers Matthew B, Müller Susanne, Knapp Stefan
Institut für Pharmazeutische Chemie, Goethe-University Frankfurt, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
Structural Genomics Consortium, Goethe-University Frankfurt, Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
ACS Chem Biol. 2025 Jan 17;20(1):94-104. doi: 10.1021/acschembio.4c00450. Epub 2025 Jan 3.
Small molecule degraders such as PROteolysis TArgeting Chimeras (PROTACs) and molecular glues are new modalities for drug development and important tools for target validation. When appropriately optimized, both modalities lead to proteasomal degradation of the protein of interest (POI). Due to the complexity of the induced multistep degradation process, controls for degrader evaluation are critical and commonly used in the literature. However, comparative studies and evaluations of cellular potencies of these control compounds have not been published so far. Here, we investigated a diverse set of ubiquitin pathway inhibitors and evaluated their potency and utility within the CRBN and VHL-mediated degradation pathway. We used the HiBiT system to measure the level of target rescue after treatment with the control compounds. In addition, the cell health was assessed using a multiplexed high-content assay. These assays allowed us to determine nontoxic effective concentrations for control experiments and to perform rescue experiments in the absence of cellular toxicity.
小分子降解剂,如蛋白酶靶向嵌合体(PROTACs)和分子胶,是药物开发的新形式,也是靶点验证的重要工具。经过适当优化后,这两种形式都会导致目标蛋白(POI)的蛋白酶体降解。由于诱导的多步降解过程的复杂性,降解剂评估的对照至关重要,并且在文献中普遍使用。然而,到目前为止,尚未发表这些对照化合物细胞活性的比较研究和评估。在这里,我们研究了多种泛素途径抑制剂,并评估了它们在CRBN和VHL介导的降解途径中的活性和效用。我们使用HiBiT系统来测量用对照化合物处理后的靶点挽救水平。此外,使用多重高内涵分析评估细胞健康状况。这些分析使我们能够确定对照实验的无毒有效浓度,并在无细胞毒性的情况下进行挽救实验。